Cite
MLA Citation
G.V. Long et al.. “24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma.” European journal of cancer, vol. 51, n.d., pp. S722–. http://access.bl.uk/ark:/81055/vdc_100030687872.0x00005c